RESUMEN
Cardiomyopathy deeply affects quality of life and mortality of patients with b-thalassemia or with transfusion-dependent myelodysplastic syndromes. Recently, a link between Nrf2 activity and iron metabolism has been reported in liver ironoverload murine models. Here, we studied C57B6 mice as healthy control and nuclear erythroid factor-2 knockout (Nrf2-/-) male mice aged 4 and 12 months. Eleven-month-old wild-type and Nrf2-/- mice were fed with either standard diet or a diet containing 2.5% carbonyl-iron (iron overload [IO]) for 4 weeks. We show that Nrf2-/- mice develop an age-dependent cardiomyopathy, characterized by severe oxidation, degradation of SERCA2A and iron accumulation. This was associated with local hepcidin expression and increased serum non-transferrin-bound iron, which promotes maladaptive cardiac remodeling and interstitial fibrosis related to overactivation of the TGF-b pathway. When mice were exposed to IO diet, the absence of Nrf2 was paradoxically protective against further heart iron accumulation. Indeed, the combination of prolonged oxidation and the burst induced by IO diet resulted in activation of the unfolded protein response (UPR) system, which in turn promotes hepcidin expression independently from heart iron accumulation. In the heart of Hbbth3/+ mice, a model of b-thalassemia intermedia, despite the activation of Nrf2 pathway, we found severe protein oxidation, activation of UPR system and cardiac fibrosis independently from heart iron content. We describe the dual role of Nrf2 when aging is combined with IO and its novel interrelation with UPR system to ensure cell survival. We open a new perspective for early and intense treatment of cardiomyopathy in patients with b-thalassemia before the appearance of heart iron accumulation.
Asunto(s)
Cardiomiopatías , Sobrecarga de Hierro , Talasemia , Animales , Masculino , Ratones , Cardiomiopatías/etiología , Cardiomiopatías/genética , Cardiomiopatías/metabolismo , Hepcidinas , Hierro/metabolismo , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/genética , Sobrecarga de Hierro/metabolismo , Factor 2 Relacionado con NF-E2/metabolismo , Calidad de Vida , Talasemia/complicaciones , Talasemia/genética , Talasemia/metabolismoRESUMEN
Using transient elastography Padeniya et al. detected steatosis and fibrosis in a cohort of young heavily iron overloaded patients with transfusion-dependent thalassaemia; steatosis was associated only with increasing body mass index, but not with iron overload and diabetes. Recently, great efforts have been devoted to eliminating or reducing iron overload and hepatitis C infection, which are well-recognised causes of liver damage. Thus, haematologists should be aware that steatosis and probably more complex metabolism alterations may be encountered very early in these patients and could be responsible for further liver damage. Commentary on: Padeniya et al. The association between steatosis and liver damage in transfusion-dependent beta thalassaemia patients. Br J Haematol 2023;200:517-523.
Asunto(s)
Hígado Graso , Sobrecarga de Hierro , Talasemia , Talasemia beta , Humanos , Talasemia/complicaciones , Talasemia/terapia , Talasemia/metabolismo , Sobrecarga de Hierro/metabolismo , Talasemia beta/complicaciones , Talasemia beta/terapia , Talasemia beta/metabolismo , Cirrosis Hepática/etiología , Hígado Graso/terapia , Hígado Graso/complicaciones , Hígado/metabolismoRESUMEN
The accumulation of unbound α-globin chains in red blood cells is a crucial pathophysiology of ß-thalassemia. IOX1 (5-carboxy-8-hydroxyquinoline) is a broad-spectrum 2-oxoglutarate (2OG)-dependent oxygenase inhibitor that can reduce α-globin mRNA expression in human cord blood erythroid progenitor cells. Therefore, IOX1 has been proposed as a potential compound for ß-thalassemia treatment through the decrease in α-globin chain synthesis. However, there is no empirical evidence regarding the consequences of IOX1 in ß-thalassemia. In this study, the therapeutic effects of IOX1 were investigated in ß0-thalassemia/hemoglobin E (HbE) erythroid progenitor cells during in vitro erythropoiesis. The results indicated that IOX1 had no impact on α-globin gene expression, but it led instead to significant decreases in γ-globin and fetal hemoglobin (HbF, α2γ2) production without affecting well-known globin regulators: KLF1, BCL11A, LRF, and GATA1. In addition, differential mRNA expression of several genes in the hypoxia response pathway revealed the induction of EGLN1, the PHD2-encoding gene, as a result of IOX1 treatment. These findings suggested that IOX1 fails to lower α-globin gene expression; on the contrary, it mediates γ-globin and HbF silencing in ß0-thalassemia/HbE erythroid progenitor cells. Because of the negative correlation of EGLN1 and γ-globin gene expression after IOX1 treatment, repurposing IOX1 to study the hypoxia response pathway and γ-globin regulation may provide beneficial information for ß-thalassemia.
Asunto(s)
Hemoglobina E , Talasemia , Talasemia beta , Adulto , Proteínas Portadoras/metabolismo , Células Eritroides/metabolismo , Células Precursoras Eritroides/metabolismo , Hemoglobina Fetal , Hemoglobina E/genética , Hemoglobina E/metabolismo , Humanos , Hipoxia/metabolismo , ARN Mensajero/genética , Talasemia/metabolismo , Globinas alfa/metabolismo , Talasemia beta/terapia , gamma-Globinas/genéticaRESUMEN
Several diseases are characterized by changes in the mechanical properties of erythrocytes. Hemolytic anemias are an example of these diseases. Among the hemolytic anemias, Sickle Cell Disease and Thalassemia are the most common, characterized by alterations in the structure of their hemoglobin. Sickle cell disease has a pathological origin in synthesizing abnormal hemoglobin, HbS. In contrast, thalassemia results in extinction or decreased synthesis of α and ß hemoglobin chains. This work presents a detailed study of biophysical and ultrastructural early erythrocytes membrane alterations at the nanoscale using Atomic Force Microscopy (AFM). Cells from individuals with sickle cell anemia and thalassemia mutations were studied. The analysis methodology in the AFM was given by blood smear and exposure of the inner membrane for ghost analysis. A robust statistic was used with 65,536 force curves for each map, ten cells of each type, with three individuals for each sample group. The results showed significant differences in cell rigidity, adhesion, volume, and roughness at early morphological alterations, bringing new perspectives for understanding pathogenesis. The sickle cell trait (HbAS) results stand out. Significant alterations were observed in the membrane properties, bringing new perspectives for the knowledge of this mutation. This work presents ultrastructural and biomechanical signatures of sickle cell anemia and thalassemia genotypes, which may help determine a more accurate biophysical description and clinical prognosis for these diseases.
Asunto(s)
Anemia de Células Falciformes , Talasemia , Anemia de Células Falciformes/genética , Anemia de Células Falciformes/metabolismo , Eritrocitos/metabolismo , Hemoglobinas/metabolismo , Humanos , Talasemia/genética , Talasemia/metabolismoAsunto(s)
Anemia de Células Falciformes/terapia , Hepatitis A/prevención & control , Hepatitis B/prevención & control , Hierro/metabolismo , Talasemia/terapia , Vacunas contra Hepatitis Viral/uso terapéutico , Adolescente , Adulto , Anemia de Células Falciformes/metabolismo , Seguridad de la Sangre , Transfusión Sanguínea , Niño , Femenino , Humanos , Hierro/análisis , Masculino , Estudios Retrospectivos , Talasemia/metabolismo , Adulto JovenRESUMEN
Hemoglobin disorders are caused due to alterations in the hemoglobin molecules. These disorders are categorized in two broad classes - hemoglobin variants and thalassemias. The hemoglobin variants arise due to point mutations in the alpha (α), beta (ß), gamma (γ), delta (δ), or epsilon (ε) globin chains of these proteins, while thalassemias are caused due to the under-production of α or ß globin chain. Hemoglobin disorders account for 7 % of the major health issues globally. Mass Spectrometry is an extensively used analytical tool in the field of protein identification, protein-protein interaction, biomarker discovery and diagnosis of several impairments including hemoglobin related disorders. The remarkable advancements in the technology and method development have enormously augmented the clinical significance of mass spectrometry in these fields. The present review describes hemoglobin disorders and the recent advancements in mass spectrometry in the detection of such disorders, including its advantages, lacunae, and future directions. The literature evidence concludes that mass spectrometry can be potentially used as a 'First Line Screening Assay' for the detection of hemoglobin disorders in the near future.
Asunto(s)
Biomarcadores/química , Subunidades de Hemoglobina/química , Hemoglobinopatías/diagnóstico , Talasemia/metabolismo , Biomarcadores/metabolismo , Cromatografía Líquida de Alta Presión , Pruebas con Sangre Seca , Electroforesis Capilar , Subunidades de Hemoglobina/metabolismo , Humanos , Espectrometría de Masas , Unión Proteica , Espectrometría de Masas en TándemRESUMEN
Extracellular vesicles (EVs) are bioactive, submicron-sized membrane vesicles released from all cell types upon activation or apoptosis. EVs including microparticles (MPs) and exosomes have emerged as important mediators of cell-to-cell communication in both normal and pathological states including thalassemia (thal). However, the role of EVs derived from ß-thal patients with iron overload (+ IO) and without iron overload (-IO) on cardiac cells is unclear. We hypothesized plasma EVs in thal patients containing ferritin (iron storage protein) and a denaturated hemoglobin-hemichrome that induce cardiac cell proliferation. The origins and numbers of EVs isolated from plasma of normal, thal (+ IO), and (- IO) patients were compared and determined for their iron and iron-containing proteins along with their effects on cardiac and endothelial cells. Data shows that MPs were originated from many cell sources with marked numbers of platelet origin. Only the number of RBC-derived MPs in thal (+ IO) patients was significantly high when compared to normal controls. Although MPs derived from both normal and thal patients promoted cardiac cell proliferation in a dose-dependent manner, only exosomes from thal patients promoted cardiac cell proliferation compared to the untreated. Moreover, the exosomes from thal (+ IO) potentially induce higher cardiac cell proliferation and angiogenesis in terms of tube number than thal (- IO) and normal controls. Interestingly, ferritin content in the exosomes isolated from thal (+ IO) was higher than that found in the MPs isolated from the same patient. The exosomes of thal patients with higher serum ferritin level also contained greater level of ferritin inside the exosomes. Apart from ferritin, there were trends of increasing hemichrome and iron presented in the plasma EVs and EV-treated H9C2 cells. Findings from this study support the hypothesis that EVs from ß-thal patients carry iron-load proteins that leads to the induction of cardiac cell proliferation.
Asunto(s)
Vesículas Extracelulares/patología , Ferritinas/análisis , Hemoproteínas/análisis , Hierro/análisis , Mioblastos Cardíacos/citología , Talasemia/patología , Adulto , Línea Celular , Proliferación Celular , Vesículas Extracelulares/metabolismo , Femenino , Ferritinas/metabolismo , Hemoproteínas/metabolismo , Células Endoteliales de la Vena Umbilical Humana , Humanos , Hierro/metabolismo , Masculino , Persona de Mediana Edad , Mioblastos Cardíacos/metabolismo , Talasemia/sangre , Talasemia/metabolismo , Adulto JovenRESUMEN
BACKGROUND: Measurements of copper and zinc in transfusion-dependent thalassemia (TDT) show contradictory results. AIM OF THE STUDY: To examine serum levels of these minerals in TDT in relation to iron overload indices and erythron variables. METHODS: This study recruited 60 children with TDT and 30 healthy controls aged 3-12 years old. RESULTS: Zinc was significantly higher in TDT children than in controls, while copper and the copper to zinc ratio were significantly lowered in TDT. Serum zinc was significantly associated with the number of blood transfusions and iron overload variables (including serum iron and TS%) and negatively with erythron variables (including hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin). Serum copper was significantly and negatively associated with the same iron overload and erythron variables. The copper to zinc ratio was significantly correlated with iron, TS%, ferritin, hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin. Albumin levels were significantly higher in TDT children than in control children. CONCLUSION: Our results suggest that the increase in zinc in children with TDT may be explained by iron loading anemia and hemolysis and the consequent shedding of high amounts of intracellular zinc into the plasma. Increased albumin levels and treatment with Desferral may further contribute towards higher zinc levels in TDT. We suggest that the elevations in zinc in TDT are a compensatory mechanism protecting against infection, inflammation, and oxidative stress. Previous proposals for prophylactic use of zinc supplements in TDT may not be warranted.
Asunto(s)
Albúminas/metabolismo , Cobre/uso terapéutico , Talasemia/terapia , Zinc/uso terapéutico , Albúminas/administración & dosificación , Niño , Preescolar , Cobre/administración & dosificación , Cobre/sangre , Femenino , Humanos , Masculino , Talasemia/sangre , Talasemia/metabolismo , Zinc/administración & dosificación , Zinc/sangreRESUMEN
Patients with thalassemia exhibit an increased risk of thrombotic events that is augmented after splenectomy. Heparanase protein enhances cancer progression, angiogenesis, and inflammation; it also activates the coagulation system through direct interaction with tissue factor (TF). Additionally, erythropoietin, which is elevated in anemic patients, up-regulates heparanase expression via the Janus kinase 2 (JAK-2) pathway. This study aimed was to explore the heparanase profile in thalassemia. Coagulation factors were analyzed via immunostaining, enzyme-linked immunosorbent assay, and heparanase procoagulant activity assay. In spleen specimens of thalassemia major patients, a higher level of heparanase staining was observed compared with control spleens resected after trauma (P < 0.001). Higher heparanase levels, heparanase and TF procoagulant activity, and erythropoietin levels were found in the plasma of 67 thalassemia major patients compared with 29 control subjects. No difference was found in pediatric patients (23 of 67) compared with adults or splenectomized versus nonsplenectomized patients. Higher levels of heparanase, TF, TF pathway inhibitor, and TF pathway inhibitor-2 were observed in liver, spleen, heart, and kidney tissues of thalassemia intermedia mice (Hbbth3/+). These protein levels significantly reduced when mice were treated with the JAK-2 inhibitor ruxolitinib (P < 0.0001). In summary, heparanase levels are elevated in thalassemia, which may contribute to thrombotic phenomena in these patients. Inhibition of heparanase or the JAK-2 pathway may reduce thrombotic risk in thalassemia.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Coagulación Sanguínea/fisiología , Glucuronidasa/metabolismo , Janus Quinasa 2/antagonistas & inhibidores , Lipoproteínas/farmacología , Trombosis/tratamiento farmacológico , Adulto , Animales , Humanos , Masculino , Ratones Endogámicos C57BL , Talasemia/tratamiento farmacológico , Talasemia/metabolismo , Tromboplastina/metabolismo , Trombosis/metabolismo , Adulto JovenRESUMEN
We report the case of a 45-year-old man with thalassemia major referred for a bone scan as a workup for generalized bone pain. Tc-MDP SPECT CT showed multiple elongated soft tissue masses along the inner aspects of ribs and along both sides of dorsal spine with calcification and mild tracer uptake. There was also a large lobulated presacral soft tissue mass displacing the bladder and involving the adjacent pelvic bone. Biopsy of mildly avid tracer uptake in pelvic soft tissue mass was extramedullary hematopoiesis confirmed by biopsy.
Asunto(s)
Hematopoyesis Extramedular , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón Único , Medronato de Tecnecio Tc 99m/metabolismo , Talasemia/diagnóstico por imagen , Talasemia/patología , Transporte Biológico , Biopsia , Humanos , Masculino , Persona de Mediana Edad , Talasemia/metabolismoAsunto(s)
Glucemia/análisis , Suplementos Dietéticos , Homeostasis , Talasemia/terapia , Sulfato de Zinc/uso terapéutico , Adolescente , Adulto , Biomarcadores , Péptido C/sangre , Niño , Complicaciones de la Diabetes/complicaciones , Complicaciones de la Diabetes/metabolismo , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/genética , Diabetes Mellitus/metabolismo , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Células Secretoras de Insulina/metabolismo , Quelantes del Hierro/uso terapéutico , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Proyectos Piloto , Talasemia/complicaciones , Talasemia/tratamiento farmacológico , Talasemia/metabolismo , Adulto Joven , Zinc/sangre , Zinc/deficiencia , Zinc/orina , Sulfato de Zinc/administración & dosificaciónRESUMEN
Erythroferrone (ERFE) is produced by erythroblasts in response to erythropoietin (EPO) and acts in the liver to prevent hepcidin stimulation by BMP6. Hepcidin suppression allows for the mobilization of iron to the bone marrow for the production of red blood cells. Aberrantly high circulating ERFE in conditions of stress erythropoiesis, such as in patients with ß-thalassemia, promotes the tissue iron accumulation that substantially contributes to morbidity in these patients. Here we developed antibodies against ERFE to prevent hepcidin suppression and to correct the iron loading phenotype in a mouse model of ß-thalassemia [Hbb(th3/+) mice] and used these antibodies as tools to further characterize ERFE's mechanism of action. We show that ERFE binds to BMP6 with nanomolar affinity and binds BMP2 and BMP4 with somewhat weaker affinities. We found that BMP6 binds the N-terminal domain of ERFE, and a polypeptide derived from the N terminus of ERFE was sufficient to cause hepcidin suppression in Huh7 hepatoma cells and in wild-type mice. Anti-ERFE antibodies targeting the N-terminal domain prevented hepcidin suppression in ERFE-treated Huh7 cells and in EPO-treated mice. Finally, we observed a decrease in splenomegaly and serum and liver iron in anti-ERFE-treated Hbb(th3/+) mice, accompanied by an increase in red blood cells and hemoglobin and a decrease in reticulocyte counts. In summary, we show that ERFE binds BMP6 directly and with high affinity, and that antibodies targeting the N-terminal domain of ERFE that prevent ERFE-BMP6 interactions constitute a potential therapeutic tool for iron loading anemias.
Asunto(s)
Anticuerpos Neutralizantes/uso terapéutico , Citocinas/antagonistas & inhibidores , Hepcidinas/metabolismo , Proteínas Musculares/antagonistas & inhibidores , Talasemia/tratamiento farmacológico , Animales , Anticuerpos Neutralizantes/farmacología , Línea Celular , Citocinas/química , Citocinas/metabolismo , Células HEK293 , Humanos , Hierro/metabolismo , Masculino , Ratones Endogámicos C57BL , Proteínas Musculares/química , Proteínas Musculares/metabolismo , Dominios Proteicos/efectos de los fármacos , Talasemia/metabolismoRESUMEN
BACKGROUND AND OBJECTIVE: Cardiac involvement due to iron overload is the most common cause of morbidity and mortality in patients with thalassemia, and many patients remain asymptomatic until the late stages. Therefore, early detection of heart problems in such patients at subclinical stages can improve the prognosis of these patients. We investigated the role of speckled tracking (SI) and tissue Doppler echocardiography (TDI) in early detection of iron overload in these patients. METHODS: 52 thalassemic patients who were receiving regular blood transfusion with normal global LV function were examined by two- and three-dimensional echocardiography. Cardiac MRI was done and T2* images were considered as the non-invasive gold standard for evaluating cardiac iron deposition. Serum ferritin level was assessed and the relationships between serum ferritin levels and echo finding with cardiac MRI T2* was investigated. RESULTS: No significant relationship was seen between serum ferritin levels and cardiac MRI T2*. Among the echocardiographic findings, septal systolic myocardial velocity (P = 0.002 and r = 0.43) and global strain (GLS) (P = 0.000 and r = 0.60) were significantly associated with T2*. A GLS < 19.5 could predict a T2* level below 20 by 82.14% sensitivity and 86.36% specificity (area under the curve = 0.87; p < 0.0001). CONCLUSION: While serum ferritin level and ejection fraction are not useful candidates, GLS may be used as a valuable marker to screen thalassemia patients for myocardial iron deposition, using a cut off value below - 19.5. This approach may facilitate the cardiac follow up, reduce the costs, and contribute to preventing deterioration of cardiac function in countries with limited availability of cardiac MRI.
Asunto(s)
Cardiomiopatías/fisiopatología , Ecocardiografía Doppler/métodos , Ventrículos Cardíacos/diagnóstico por imagen , Hierro/metabolismo , Imagen por Resonancia Cinemagnética/métodos , Volumen Sistólico/fisiología , Talasemia/diagnóstico , Enfermedades Asintomáticas , Biomarcadores/metabolismo , Cardiomiopatías/diagnóstico , Cardiomiopatías/etiología , Femenino , Ferritinas/sangre , Estudios de Seguimiento , Ventrículos Cardíacos/metabolismo , Ventrículos Cardíacos/fisiopatología , Humanos , Masculino , Miocardio/metabolismo , Pronóstico , Estudios Retrospectivos , Talasemia/complicaciones , Talasemia/metabolismo , Función Ventricular Izquierda/fisiología , Adulto JovenAsunto(s)
Anemia de Células Falciformes , Antígenos CD34 , Células de la Médula Ósea , Regulación de la Expresión Génica , Análisis de Secuencia de ARN , Análisis de la Célula Individual , Talasemia , Anemia de Células Falciformes/genética , Anemia de Células Falciformes/metabolismo , Anemia de Células Falciformes/patología , Células de la Médula Ósea/metabolismo , Células de la Médula Ósea/patología , Niño , Femenino , Humanos , Masculino , Talasemia/genética , Talasemia/metabolismo , Talasemia/patologíaRESUMEN
The morbidity and mortality in thalassemia patients are predominantly caused by iron overload cardiomyopathy (IOC). Iron-induced cardiac intracellular Ca2+ ([Ca2+]i) dysregulation is among the core pathophysiological processes in IOC-related heart failure. Although cardioprotective roles of deferiprone (DFP) and N-acetylcysteine (NAC) have been reported, their effect on cardiac [Ca2+]i transients and Ca2+-regulatory protein expression in thalassemic mice is unknown. In the present study, iron overload condition was induced in wild-type (WT) and heterozygous ß-thalassemic (HT) mice by a high-iron diet. The iron-overloaded mice subsequently received a vehicle, DFP, NAC, or DFP plus NAC co-therapy. In both WT and HT iron-overloaded mice, DFP and NAC had similar efficacy in decreasing plasma non-transferrin-bound iron, decreasing cardiac iron concentration (CIC) and relieving systolic dysfunction. DFP plus NAC co-therapy, however, was better than the monotherapy in reducing CIC and restoring cardiac [Ca2+]i transient amplitude and rising rate. All regimens produced no change in cardiac Ca2+-regulatory protein expression. We provided the first evidence regarding the synergistic effect of combined iron chelator-antioxidant therapy on cardiac [Ca2+]i homeostasis in iron-overloaded thalassemic mice, with consistent improvement of cardiac contractility.
Asunto(s)
Acetilcisteína/farmacología , Calcio/metabolismo , Deferiprona/farmacología , Quelantes del Hierro/farmacología , Sobrecarga de Hierro/metabolismo , Miocardio/metabolismo , Talasemia/metabolismo , Animales , Corazón/efectos de los fármacos , Homeostasis , Ratones Endogámicos C57BL , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/metabolismo , Función Ventricular Izquierda/efectos de los fármacosRESUMEN
Thalassemia is one of the most common monogenic hereditary disorders. Despite noticeable advances made in prevention strategies, it is still highly prevalent in the Iranian population. A key approach to management and early diagnosis of the disease is through revealing the regions with high prevalence and determining common genetic and phenotypic diversity. In the current study Hemoglobin H (HbH) disease patients were analyzed as the most common form of thalassemia intermedia in Iran. A total of 80 patients suspected of being thalassemic according to their mild to moderate anemia, microcytosis and normal iron levels were included in this study at the hemoglobinopathy and thalassemia center of Ahvaz University of Medical Science. Patients were analyzed for hematological parameters and HbH mutations using Multiplex Gap Polymerase Chain Reaction and Multiplex Amplification Refractory Mutation System. Twelve mutations were detected in the studied population. The most common genotype was -α3.7/--MED (45%) followed by Homozygote αPoly A2 (17.5%). A total of ten different alpha-globin (α-globin) mutations were observed in patients which --MED, being the most common mutation (26.27%), followed by -α3.7 (24.37%) and αpolyA2(A>G) (18.12%). Hematological parameters such as Hb, MCV, MCH and HbH were assessed and results showed that they varied significantly among genotypes, adjusted to age and gender. This study reveals a highly diverse range of HbH patients different from what was thought in terms of both genotype and phenotype in the Khuzestan region of Iran. These findings could contribute to improve the thalassemia managing policies in this province.
Asunto(s)
Talasemia/genética , Talasemia alfa/genética , Adolescente , Adulto , Femenino , Estudios de Asociación Genética/métodos , Genotipo , Humanos , Irán/epidemiología , Masculino , Mutación , Fenotipo , Talasemia/metabolismo , Adulto Joven , Globinas alfa/genética , Globinas alfa/metabolismo , Talasemia alfa/metabolismo , Talasemia beta/genéticaRESUMEN
We explored the severity and risk factors for cardiac and liver iron overload (IOL) in 69 thalassemia patients who underwent T2* magnetic resonance imaging (T2* MRI) in a Malaysian tertiary hospital from 2011 to 2015. Fifty-three patients (76.8%) had transfusion-dependent thalassemia (TDT) and 16 (23.2%) had non transfusion-dependent thalassemia (NTDT). Median serum ferritin prior to T2* MRI was 3848.0 µg/L (TDT) and 3971.0 µg/L (NTDT). Cardiac IOL was present in 16 (30.2%) TDT patients and two (12.5%) NTDT patients, in whom severe cardiac IOL defined as T2* <10 ms affected six (11.3%) TDT patients. Liver IOL was present in 51 (96.2%) TDT and 16 (100%) NTDT patients, 37 (69.8%) TDT and 13 (81.3%) NTDT patients were in the most severe category (>15 mgFe/gm dry weight). Serum ferritin showed a significantly strong negative correlation with liver T2* in both TDT (rs = -0.507, p = 0.001) and NTDT (r = -0.762, p = 0.002) but no correlation to cardiac T2* in TDT (r = -0.252, p = 0.099) as well as NTDT (r = -0.457, p = 0.100). For the TDT group, regression analysis showed that cardiac IOL was more severe in males (p = 0.022) and liver IOL was more severe in the Malay ethnic group (p = 0.028) and those with higher serum ferritin levels (p = 0.030). The high prevalence of IOL in our study and the poor correlation between serum ferritin and cardiac T2* underline the need to routinely screen thalassemia patients using T2* MRI to enable the early detection of cardiac IOL.
Asunto(s)
Sobrecarga de Hierro/etiología , Talasemia/metabolismo , Adulto , Transfusión Sanguínea , Diagnóstico Precoz , Femenino , Ferritinas/sangre , Humanos , Sobrecarga de Hierro/diagnóstico por imagen , Hígado/metabolismo , Hígado/patología , Imagen por Resonancia Magnética , Malasia/epidemiología , Masculino , Miocardio/metabolismo , Miocardio/patología , Prevalencia , Factores de Riesgo , Factores Sexuales , Talasemia/epidemiologíaRESUMEN
Transfusion-dependent thalassaemia (TDT) requires red blood cell concentrates (RBCC) to prevent complications of anaemia, but carries risk of infection. Pathogen reduction of RBCC offers potential to reduce infectious risk. We evaluated the efficacy and safety of pathogen-reduced (PR) Amustaline-Glutathione (A-GSH) RBCC for TDT. Patients were randomized to a blinded 2-period crossover treatment sequence for six transfusions over 8-10 months with Control and A-GSH-RBCC. The efficacy outcome utilized non-inferiority analysis with 90% power to detect a 15% difference in transfused haemoglobin (Hb), and the safety outcome was the incidence of antibodies to A-GSH-PR-RBCC. By intent to treat (80 patients), 12·5 ± 1·9 RBCC were transfused in each period. Storage durations of A-GSH and C-RBCC were similar (8·9 days). Mean A-GSH-RBCC transfused Hb (g/kg/day) was not inferior to Control (0·113 ± 0·04 vs. 0·111 ± 0·04, P = 0·373, paired t-test). The upper bound of the one-sided 95% confidence interval for the treatment difference from the mixed effects model was 0·005 g/kg/day, within a non-inferiority margin of 0·017 g/kg/day. A-GSH-RBCC mean pre-transfusion Hb levels declined by 6·0 g/l. No antibodies to A-GSH-RBCC were detected, and there were no differences in adverse events. A-GSH-RBCCs offer potential to reduce infectious risk in TDT with a tolerable safety profile.
Asunto(s)
Acridinas/metabolismo , Eritrocitos , Glutatión/metabolismo , Compuestos de Mostaza Nitrogenada/metabolismo , Talasemia/metabolismo , Adolescente , Adulto , Transfusión Sanguínea , Niño , Índices de Eritrocitos , Femenino , Hemoglobinas/metabolismo , Humanos , Masculino , Talasemia/etiología , Talasemia/terapia , Adulto JovenRESUMEN
Transfusion combined with chelation therapy for severe ß thalassemia syndromes (transfusion-dependent thalassemia [TDT]) has been successful in extending life expectancy, decreasing comorbidities and improving quality of life. However, this puts lifelong demands not only on the patients but also on the health care systems that are tasked with delivering long-term treatment and comprehensive support. Prevention programs and curative approaches are therefore an important part of overall strategy. Curative treatments alter the dynamic of a patient's health care costs, from financial commitment over 50 years, into a potential "one-off" investment. Since the 1980s, this has usually been available only to the 30% or so of young children with matched sibling donors. By improving the safety of matched related donors and haploidentical hematopoietic stem cell transplants, the potential size of the donor pool for curative therapies may be increased. Recent advances in gene therapy demonstrate that even patients lacking a matched donor can be rendered transfusion independent with an autograft of genetically modified autologous stem cells, with a low short-term risk. Noncurative treatments are also of potential value by decreasing use of blood and chelators and decreasing hospital visits. An example is luspatercept, an activin-receptor trap that modifies transforming growth factor-ß signaling, thereby increasing the efficiency of erythropoiesis. This has entered phase 3 clinical trials for TDT and non-TDT and, usefully increases in both Hb and quality of life in non-TDT as well as decreasing transfusion requirements in TDT. Other novel noncurative treatments are entering clinical trials such improvement of erythropoiesis through pharmacological manipulation of hepcidin and iron metabolism.